BackTCM Biotech International Overview

TCM Biotech International Current Assets

Track TCM Biotech International's current assets ($860M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$858.46M
↑ 5.72% YoYΔ $46.48M vs prior year quarter

Peer trimmed avg / median

Loading

TCM Biotech International Current Assets History

Loading

TCM Biotech International vs. peers: Current Assets Comparison

Loading

TCM Biotech International Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

TCM Biotech International (4169.TWO) FAQ

TCM Biotech International's current assets stands at $860M as of December 2025. That compares with $810M in the prior-year period — up 5.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

TCM Biotech International reported $860M in current assets versus $810M a year earlier — a 5.7% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $810M in the prior-year period — up 5.7% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how TCM Biotech International's current assets evolved across reporting periods, while the comparison chart places 4169.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. TCM Biotech International's reading of $860M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.